KZR
Kezar Life SciencesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
KZR Profile
Kezar Life Sciences, Inc.
A clinical-stage biopharmaceutical company focus on treatments for immune-mediated and oncologic disorders
Pharmaceutical
02/19/2015
06/21/2018
NASDAQ Stock Exchange
55
12-31
Common stock
4000 Shoreline Court, Suite 300, South San Francisco, CA 94080
--
Kezar Life Sciences, Inc., was incorporated under the laws of the State of Delaware on February 19, 2015. The company is a clinical-stage biotechnology company developing novel small molecule therapies for the treatment of unmet needs in immune-mediated diseases and cancer. The company is advancing two drug development programs that utilize different regulators of cell function: the first targets the immunoproteasome, which is responsible for many key aspects of protein degradation in immune system cells and drives immune cell function, and the second targets the Sec61 transposon.
